Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T09:17:10.240Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine plasma levels and dosing strategies in patients with treatment-refractory schizophrenia

Published online by Cambridge University Press:  13 June 2014

Peter F Buckley ,
Philip Cola ,
Mitsuru Hasegawa ,
Christine Lys  and
Paul Thompson
Peter F Buckley
Affiliation:
Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, Hanna Pavilion, 2040 Abington Road, Cleveland, Ohio 44106, USA
Philip Cola
Affiliation:
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA
Mitsuru Hasegawa
Affiliation:
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA
Christine Lys
Affiliation:
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA
Paul Thompson
Affiliation:
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective: To determine the effect on clinical response to clozapine of increasing the plasma levels of clozapine and its major metabolite N-desmethylclozapine in 19 patients with schizophrenia who had plasma clozapine levels ≤ 370ng/ml, a level previously determined to identify patients who were unlikely to have an adequate response to clozapine.

Method: The dosage of clozapine was increased by 20% in 11 patients and left unaltered in the other eight patients. Clozapine and N-desmethylclozapine plasma levels were measured after six weeks at the higher dose.

Results: Nine of the 11 patients in whom clozapine dosage was increased subsequently achieved plasma clozapine levels ≥ 370ng/ml. However, in this group of patients who already had partially responded to clozapine, increasing the dosage of clozapine did not produce additional clinical improvement.

Conclusion: Clozapine plasma levels are useful in clinical practice to guide dosage strategies. However, these results suggest that increasing the dosage of clozapine to achieve plasma levels ≥ 370ng/ml is unlikely to produce further improvement in patients who have already achieved a partial response to clozapine at plasma levels ≤ 370ng/ml.

Type
Original Papers
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 3 , September 1997 , pp. 85 - 88
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kane, JM, Honigfeld, G, Singer, Jet al.Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96.CrossRefGoogle ScholarPubMed
2.Meltzer, HY. Treatment of the neuroleptic-non-responsive schizophrenic patient. Schiz Bull 1992; 18: 515–42.CrossRefGoogle ScholarPubMed
3.Meltzer, HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(17): 36–43.CrossRefGoogle Scholar
4.Hagger, C, Buckley, P, Kenny, JT, et al.Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702–12.CrossRefGoogle ScholarPubMed
5.Lee, MA, Thompson, PA, Meltzer, HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994; 55(9, suppl B): 82–7.Google ScholarPubMed
6.Goldberg, TE, Weinberger, DR. Neuropsychological function and clozapine treatment. J Clin Psychiatry 1994; 55(Suppl 9): 88–92.Google Scholar
7.Meltzer, HY, Burnett, S, Bastani, B, et al.Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990; 41(8): 892–7.Google ScholarPubMed
8.Meltzer, HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989; 46: 672.CrossRefGoogle ScholarPubMed
9.Povlsen, J, Noring, U, Fog, Ret al.Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients, treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71:176–85.CrossRefGoogle Scholar
10.Hiemke, C, Weigmann, H, Hartter, S. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14(4): 279–81.CrossRefGoogle ScholarPubMed
11.Perry, PJ, Miller, DD, Arndt, SVet al.Clozapine and non-clozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231–5.Google Scholar
12.Hasegawa, M, Gutierrez-Esterinou, R, Way, Let al.Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia. Effect of Smoking. J Clin Psychopharmacol 1993; 13(6): 383–90.CrossRefGoogle ScholarPubMed
13.Lieberman, JA, Kane, JM, Safferman, AZ. Predictors of response to clozapine. J Clin Psychiatry 1994; 55(9, suppl B): 126–8.Google ScholarPubMed
14.Miller, DD, Fleming, F, Holman, TLet al.Plasma clozapine concentrations as a predictor of clozapine response: a follow-up study. J Clin Psychiatry 1994; 55(9, suppl B): 117–21.Google ScholarPubMed
15.Potkin, SG, Bera, R, Gulasekaram, Bet al.Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55(9, suppl B): 133–6.Google ScholarPubMed
16.Ackenheil, M, Brau, H, Burkhart, Aet al.Antipsychotische wirksamkeit im verhaltnis sum plasmaspiegel von Clozapin. Arzneimittelforschung 1976; 26: 1156–8.Google Scholar
17.Thorup, M, Fog, R. Clozapine treatment of schizophrenic patients: plasma concentration and coagulation factors. Acta Psychiatr Scand 1977; 55:123–6.CrossRefGoogle ScholarPubMed
18.Brau, VH, Burkhart, A, Pacha, Wet al.Benziehungen zwischen Wirkungen und Plasmaspiegel von Clozapine. Arzneimittelforschung 1978: 1300–1.Google Scholar
19.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Revised. Washington DC, 1987.Google Scholar
20.Endicott, J, Spitzer, RL. A diagnostic interview. The Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35: 837–44.CrossRefGoogle ScholarPubMed
21.Rhodes, HM, Overall, JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988; 10: 101–4.Google Scholar
22.Lovdahl, JM, Perry, PJ, Miller, DD. The assay of clozapine and N-desmethylclozapine in human plasma by high performance liquid chromatography. Ther Drug Monit 1991; 13: 69–72.CrossRefGoogle ScholarPubMed
23. SAS. SAS Institute Inc, 1995.Google Scholar
24.Kronig, MH, Munne, RA, Szymanski, Set al.Plasma clozapine levels and clinical response in treatment-refractory schizophrenia. Am J Psychiatry 1995; 152: 179–82.Google Scholar